CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
